Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies

20260 citationsJournal Articlehybrid Open Access

Authors

Although the sample size is small, these findings support the clinical benefit of zanidatamab treatment for HER2-positive SGC.

Good health and well-being

Published in: Clinical Cancer Research

Field-Weighted Citation Impact: 0.00